RPL 554

Drug Profile

RPL 554

Alternative Names: RPL554

Latest Information Update: 17 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Developer Verona Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Imines; Isoquinolines; Small molecules; Urea compounds
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Allergic rhinitis; Asthma; Asthma

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
  • Discontinued Allergic rhinitis

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 06 Sep 2018 Updated efficacy data from two phase II trials in Chronic obstructive pulmonary disease released by Verona Pharma
  • 07 Aug 2018 Verona Pharma plans a pivotal phase III trial for Chronic obstructive pulmonary disease in second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top